NCT05217641View on ClinicalTrials.gov

A Clinical Trial to Evaluate the Safety and Immunogenicity of BG505 MD39.3, BG505 MD39.3 gp151, and BG505 MD39.3 gp151 CD4KO HIV Trimer mRNA Vaccines in Healthy, HIV-uninfected Adult Participants

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

February 11, 2022

Primary Completion Date

July 17, 2023

Study Completion Date

June 24, 2027

Conditions
HIV Infections
Interventions
BIOLOGICAL

BG505 MD39.3 mRNA

Administered by IM injection

BIOLOGICAL

BG505 MD39.3 gp151 mRNA

Administered by IM injection

BIOLOGICAL

BG505 MD39.3 gp151 CD4KO mRNA

Administered by IM injection

Trial Locations (10)

10065

New York Blood Center CRS [31801], New York

14642

University of Rochester Vaccines to Prevent HIV Infection CRS [31467], Rochester

15213

University of Pittsburgh CRS [1001], Pittsburgh

19104

Penn Prevention CRS [30310], Philadelphia

30329

Columbia P&S CRS [30329], New York

35222

Alabama CRS [31788], Birmingham

90038

UCLA Vine Street Clinic CRS [31607], Los Angeles

98104

Seattle Vaccine and Prevention CRS [30331], Seattle

02115

Bidmc Vcrs [32077], Boston

Brigham and Women's Hospital Vaccine CRS [30007], Boston

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

Department of Health and Human Services

FED

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH